Go to the list of all blogs
Serhii Bond's Avatar
published in Blogs
Aug 03, 2023

Therapy Stock Review: Outstanding 10.96% Weekly Gain $BIIB, $URGN, $ALLO

Thriving in Therapy: A Deeper Look into the Biotech and Pharmaceutical Theme

Overview of the Therapy Theme
Theme Therapy +10.96% - 1W change
Swing trader: Long-Short Equity Strategy (TA&FA) Annualized Return + 64% and Swing trader: High Capitalization (TA) Annualized Return + 7%

As the world grapples with various health challenges, the need for innovative therapeutic solutions cannot be overstated. In the financial market, the Therapy theme represents an intriguing investment opportunity. This theme focuses on biotech and pharmaceutical companies that discover, develop, manufacture, and deliver therapies for treating various diseases and disorders. The industry is part of the overall healthcare field but has a specific focus on the development of treatments to cure or prevent diseases.

This theme includes tickers such as $ACRS, $ALLO, $ALNY, $ARVN, $BIIB, $BPMC, $EVLO, $INMB, $KRYS, $LIVN, $OCUL, $URGN, $USPH, and $VKTX. These companies are diverse in their operations but united by their commitment to developing and delivering life-saving therapies.

Market Capitalization Analysis

These therapy-themed companies boast a collective average market capitalization of $5.8B, with individual valuations ranging from $153.8M to a whopping $39.1B. Leading the pack is Biogen ($BIIB) with the highest valuation of $39.1B, while Immune Bio Inc. ($INMB) trails with the smallest market cap at $153.8M.

A Peek into Performance: Allogene Therapeutics ($ALLO), UroGen Pharma ($URGN), and Biogen ($BIIB)

Allogene Therapeutics ($ALLO)

Allogene Therapeutics has demonstrated some volatility in its performance. For instance, the company experienced a notable downtrend with a -6.62% decrease on July 25, 2023, and a -8.49% fall on July 15, 2023. However, the company also showed resilience with a +9.61% jump on July 7, 2023, indicating an uptrend reversal. This fluctuation in performance demonstrates the dynamic nature of the biotech industry.

UroGen Pharma ($URGN)

UroGen Pharma, on the other hand, has been a high flyer in the Therapy theme, exhibiting the highest price growth at 129.64%. This significant growth reflects the company's innovative approach to developing and commercializing therapies designed to change the standard of care for urological pathologies.

Biogen ($BIIB)

Biogen, the heavyweight in this theme, demonstrates why it commands such a massive market capitalization. With a valuation of $39.1B, the company continues to be a major player in the industry, providing a wide array of therapies for diseases such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy, among others.

Volume Fluctuation Analysis

The average weekly volume growth across all stocks in the group stands at 95.5%. Allogene Therapeutics ($ALLO) experienced a record-breaking daily growth of 1,009% of the 65-Day Volume Moving Average on June 24, 2023. On May 26, 2023, US Physical Therapy ($USPH) had a similar record-breaking daily growth of 1,369% of the 65-Day Volume Moving Average. Krystal Biotech ($KRYS) also experienced a significant two-day consecutive volume increase, resulting in a daily growth of 178% of the 65-Day Volume Moving Average on May 25, 2023. These volume fluctuations provide an insightful look into investor interest and trading activity within the Therapy theme.

Fundamental Analysis Ratings

Fundamental analysis ratings provide another valuable perspective on the health and potential of companies within this theme. On average, companies in this theme have a Valuation Rating of 72, P/E Growth Rating of 88, a Price Growth Rating of 51, an SMR Rating of 91, and a Profit Risk Rating of 83. The Seasonality Score stands at 15. These scores indicate the overall health and potential for growth of these companies, offering another piece of the investment decision puzzle.

The Therapy theme offers a myriad of opportunities for investors who are passionate about healthcare and the development of novel therapeutic treatments. The performance of the companies under this theme not only shows their potential for growth but also the crucial role they play in improving global health outcomes.

Related Ticker: BIIB, ACRS, ALLO, ALNY, ARVN, BPMC, EVLO, INMB, KRYS, URGN, OCUL, LIVN, USPH, VKTX

BIIB in downward trend: price may drop because broke its higher Bollinger Band on May 15, 2024

BIIB broke above its upper Bollinger Band on May 15, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 36 similar instances where the stock broke above the upper band. In of the 36 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for BIIB moved out of overbought territory on May 16, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 47 cases where BIIB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on June 17, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on BIIB as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BIIB turned negative on June 17, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 139 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BIIB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.110) is normal, around the industry mean (5.632). P/E Ratio (26.955) is within average values for comparable stocks, (48.974). BIIB's Projected Growth (PEG Ratio) (8.807) is slightly higher than the industry average of (3.004). Dividend Yield (0.000) settles around the average of (0.164) among similar stocks. P/S Ratio (3.181) is also within normal values, averaging (3.643).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock worse than average.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Bristol-Myers Squibb Co (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 86.34B. The market cap for tickers in the group ranges from 72.83K to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 1%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 1%. SCLX experienced the highest price growth at 48%, while GIFLF experienced the biggest fall at -10%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 9%. For the same stocks of the Industry, the average monthly volume growth was -14% and the average quarterly volume growth was -72%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 33
P/E Growth Rating: 49
Price Growth Rating: 57
SMR Rating: 63
Profit Risk Rating: 72
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
BIIBDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of therapies for people living with neurological, autoimmune and hematologic disorders

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Biotechnology
Address
225 Binney Street
Phone
+1 617 679-2000
Employees
7570
Web
https://www.biogen.com
Ad is loading...
Discover the dynamic world of cryptocurrency trading with Tickeron's AI analysis. Capitalize on bullish and bearish patterns in Origin Protocol (OGN.X), with gains up to 27.80%. Stay ahead with Tickeron's real-time insights and make informed trading decisions. #CryptoTrading #AIAnalysis #OriginProtocol #InvestSmart
#latest#popular#patterns#artificial_intelligence#trading#technical_analysis
Dive into the world of trading excellence with our Best AI Robot of the week! In a market characterized by growth, the key to maximizing profits lies not only in mainstream large-cap stocks but also in exploring opportunities across different market segments.
This article delves into the performance of AI trading robots, specifically those utilizing the "Swing trader: Long-Short Equity Strategy (TA&FA)." These bots showcased their prowess by delivering a notable +4.98% gain while engaging in MRNA trades over the previous week. Beyond mere statistics, we explore the technical indicators and recent earnings report of MRNA to shed light on the underlying dynamics influencing the stock.
Artificial intelligence (AI) trading bots have become powerful tools for investors seeking active trading opportunities. In a recent analysis conducted on the "Day Trader: High Volatility Stocks for Active Trading (TA&FA)" platform, AI trading bots exhibited impressive performance, generating a noteworthy +4.81% gain while actively trading Shopify (SHOP) over the course of the previous week.
In the dynamic world of finance, strategic asset acquisition is a game-changer. Recently, a group of stocks within this domain has been in the spotlight, showcasing notable performances and intriguing patterns. This article delves into the recent movements of these stocks, focusing on key indicators, market capitalization, notable price events, and volume dynamics.
The Tickeron quant team is delighted to introduce our best robot of the week tailored for Trend Traders. Our sophisticated AI Robot, has been designed for manual trading enthusiasts who value independent signal selection.
Tickeron's Quant team is delighted to introduce our latest AI-powered robot designed for trading small-cap stocks, employing a distinctive fundamental stock analysis algorithm. This algorithm, renowned for its blend of in-depth analysis and intuitive signal-following capabilities, is well-suited for both novice and seasoned traders.
The Tickeron quant team proudly presents our top-performing AI robot for swing traders. This robot stands out with its remarkable accuracy, empowering traders to capitalize on diverse market conditions and transaction types. Demonstrating its proficiency, it achieved profitability in short trades during last week's strong uptrend in the US stock markets.
One such example is the "Trend Trader: Popular Stocks (TA&FA)" platform, where AI trading robots demonstrated their prowess by generating a notable gain while actively trading Adobe Inc. (ADBE) over the previous week. In this article, we delve into a technical analysis of ADBE's recent performance, shedding light on key indicators and recent earnings results.
​​​​​​​The railroads sector, encompassing prominent players such as Canadian Pacific Railway (CP), CSX Corporation (CSX), Norfolk Southern Corporation (NSC), Canadian National Railway Company (CNI), and Union Pacific Corporation (UNP), has undergone a noteworthy surge in performance over the past week. However, a closer examination reveals a complex landscape marked by negative outlook signals and fluctuating market dynamics.
The Tickeron quant team is excited to introduce our premier AI robot, specifically optimized for Swing Traders. This tool represents the pinnacle of our technological advancements in trading algorithms. Excelling in the market, it has achieved an impressive feat, earning twice as much as the S&P 500 in just the past week.
In the whirlwind of the current mergers and acquisitions frenzy, investors are reaping substantial rewards as stocks within the merger industry theme surged by an impressive 20.9% on average over the past month.
The Tickeron quant team is delighted to introduce our top-performing AI robot tailored for beginners. Our AI Robot specializes in navigating the high-tech stocks within the NASDAQ 100 index, renowned for their liquidity and moderate volatility—making them an ideal choice for novice traders.
In the dynamic landscape of the US stock markets, where unpredictability has become the norm, finding a trading strategy that not only thrives in periods of growth but also shields against sharp corrections is paramount.
The Tickeron quant team proudly introduces our premier AI Robot, tailor-made for trend traders who prefer manual trading and selecting their own signals. This AI Robot stands out with its impressive track record of consistent trading predictions, empowering traders to align their decisions with personal preferences.
Tickeron is excited to highlight the exceptional performance of our top AI robot this week, given the recent downturn in major US stock indices. While the SP500, NASDAQ 100, and Dow Jones Industrial all experienced declines, our AI robot, thanks to its well-calibrated diversification across various industries, demonstrated remarkable resilience.
As the trading week came to a close on Friday, there were notable movements across various asset classes:
Tickeron's quant team diligently monitors developed trading algorithms daily to determine the most effective ones. Today, we are delighted to present three of the best robots tailored for swing traders, showcasing consistently positive results over several months, irrespective of market conditions. This week, they underscored their efficacy by yielding impressive gains across various stocks, even as major US stock indexes dipped.
Tickeron is excited to highlight the exceptional performance of our top AI robot this week. The US stock market has experienced a consistent upward trend for the past five months, heightening the anticipation of a forthcoming correction with each passing day.
Introducing our top-performing best AI Robot of the week, designed by Tickeron's expert quant team for trading small-cap stocks. This algorithm blends classical and proprietary technical indicators, honed through advanced machine learning, to empower users with effective portfolio diversification and maximum profitability in the dynamic market.